Carregant...
Characterizing new users of NSAIDs before and after rofecoxib withdrawal
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: • Public concern regarding the cardiovascular safety of the COX-2 inhibitors began with the withdrawal of rofecoxib from the market in September 2004. • Since then, a myriad of evidence has pointed towards an adverse cardiovascular effect of other COX-2 inhi...
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Blackwell Publishing Ltd
2007
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2203243/ https://ncbi.nlm.nih.gov/pubmed/17054665 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2006.02784.x |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|